BEACON introduces yet another blockbuster anticancer drug, Lenvatinib

BEACON introduces another promising multikinase inhibitor, Lenvatinib, under the brand name of Lenvanix for global market.

• First new Front-Line treatment option for Hepatocellular Carcinoma (HCC).

• First Tyrosine Kinase Inhibitor (TKI) for locally recurrent or metastatic, progressive RAI-refractory Differentiated Thyroid Cancer (DTC).

• Lenvatinib plus everolimus is the first and only FDA-approved regimen for advanced Renal Cell Cancer (RCC) treatment.

   Lenvanix is an oral capsule preparation which is available in the strengths of 10 mg & 4 mg. 

To know more visit our product website: www.lenvanix.com